Hormonal
GLP-1 receptor agonists (Liraglutide 3.0 mg and Semaglutide 2.4 mg) produce superior weight loss and cardiovascular risk reduction compared to other pharmacotherapies, making them first-line pharmacological options for high-risk patients.
If lifestyle changes alone are insufficient, GLP-1 medications like Semaglutide or Liraglutide are the most effective pharmacological options, offering significant weight loss (up to 12+ kg) and cardiovascular benefits. They require weekly or daily injections and slow dose titration to manage side effects. Discuss cost and insurance coverage with your provider to determine if this is a viable long-term strategy.
Liraglutide (3.0 mg) and semaglutide (2.4 mg) have shown the strongest weight loss effects among currently approved anti-obesity drugs... These drugs should be considered as the first choice for obese patients with type 2 diabetes if conditions permit.
Why this rating
Based on multiple large-scale clinical trials (STEP, SURMOUNT, etc.) and meta-analyses cited in the guideline.
Source
Guidelines for obesity clinic consultations in primary healthcare clinics
Jee‐Hyun Kang et al. · Journal of Korean Medical Association · 2024
DOI 10.5124/jkma.2024.67.4.240
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →